Merck/Endocyte Mulling Vintafolide’s Future After Failure In Ovarian Cancer

Endocyte is potentially propelled back to a Phase I company after its nearest commercial prospect flops and its collaboration with Merck is expected to disintegrate now that the drug missed PFS in ovarian cancer.